AI assistant
Fagron N.V. — Major Shareholding Notification 2012
Mar 16, 2012
3949_mrq_2012-03-16_3271064c-7f3a-4fb0-a42c-bb3a6fc38770.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
DISCLOSURE OF RECEIVED NOTIFICATION
Waregem (Belgium) / Rotterdam (Netherlands)1 , 16 March 2012 (7.30 a.m.) – Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Arseus NV is announcing today that the number of shares held by Arseus NV has fallen below the disclosure threshold of 3%.
The number of own shares held by Arseus NV has decreased from 1,097,585 shares to 760,345 shares. This decrease is the result of the transfer of € 4 million in own shares as payment for the acquisition of the Brazilian Pharma Nostra in 2011. On 13 March 2012, Arseus transferred 337,240 shares at a price of € 11.8610 per share.
Based on the total of 31,216,888 (total number of voting rights) and the relevant notifications received by Arseus, today the shareholder structure of Arseus is as follows:
| Number of shares | % of the total | |
|---|---|---|
| EnHold NV | 8,166,908 | 26.16% |
| Alychlo NV/Coucke | 3,528,080 | 11.30% |
| BNP Paribas Investment Partners SA | 1,546,052 | 4.95% |
| Arseus NV | 760,345 | 2.44% |
| Public | 17,215,503 | 55.15% |
The original notification forms are available at www.arseus.com. Detailed information about the acquisition of the Brazilian Pharma Nostra is available in the press release of 11 July 2011. This press release can be viewed at www.arseus.com.
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
1 This press release was sent out by Arseus NV and Arseus BV.
For more information:
Constantijn van Rietschoten Director of Corporate Communications +31 88 33 11 222 (office) +31 6 536 91 585 (mobile) [email protected]
Arseus profile
Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in Europe, the US, Brazil and Argentina. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICTsolutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.